Osteoporosis Disease Specific Site

1. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-26.

2. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-15.

3. Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects. J Obstet Gynaecol. 2003 May;23(3):278-81.

4. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
JAMA. 2003 May 21;289(19):2525-33.

5. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis.
Obstet Gynecol. 2003 Apr;101(4):711-21.

6. Osteoporosis treatment in elderly hyperthyroid male patients.
J Endocrinol Invest. 2002;25(10 Suppl):98-100.

7. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.
Clin Ther. 2002 Nov;24(11):1871-86.

8. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med. 2002 Dec 3;137(11):875-83.

9. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
J Bone Miner Res. 2002 Nov;17(11):1988-96.

10.14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
J Rheumatol. 2002 Sep;29(9):1965-74.

11. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 May 21;136(10):742-6.

12. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

13. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Am J Gastroenterol. 2002 Jan;97(1):58-64.

Risedronate:

1. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int. 2003 Jun;14(5):437-41.

2. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003 Feb;88(2):542-9.

3. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002 Nov;31(5):620-5.

4.14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
J Rheumatol. 2002 Sep;29(9):1965-74.

5. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Osteoporos Int. 2002;13(6):501-5.

6. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Calcif Tissue Int. 2002 Aug;71(2):103-11.

7. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001 Oct;69(4):242-7.

8. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001 May;86(5):1890-7.

9. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone. 2001 Jan;28(1):108-12.